In context
Mazdutide acts on GLP-1 and glucagon receptors. A phase 3 placebo-controlled study in China examined bodyweight outcomes in adults with overweight or obesity. [1]
At a glance
- Type
- Peptide / related clinical research
- Regulatory context
- The cited source describes research, not a determination of present marketing authorisation. Country, formulation and indication must be checked separately.
- Evidence
- Eligibility thresholds, population and follow-up define the trial's scope. A publication is not itself a record of approval in the United States or Thailand.
How to interpret this evidence
Eligibility thresholds, population and follow-up define the trial's scope. A publication is not itself a record of approval in the United States or Thailand. [1]
Safety and clinical context
The evidence described here does not establish safety for unsupervised use. Product identity, route, formulation, interactions and long-term effects cannot be inferred from a study category.
Evidence and authorisation depend on the product, formulation, indication and country. US labelling does not establish Thai authorisation. This guide is educational and is not a dosing or self-treatment protocol.
Primary sources
Read the underlying source and its limitations. A study citation does not by itself establish efficacy or approval.
- Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. pubmed.ncbi.nlm.nih.gov